EDAP TMS SA annual report, Q4 FY2021

EDAP TMS S.A. — FY2021 Form 20-F

Reporting period: Fiscal year ended December 31, 2021; filed April 8, 2022. This is an annual report, not a standalone Q4 filing, and the supplied text does not provide separate Q4 financial results. Financial statements are prepared under U.S. GAAP and presented in euros unless noted.

Business context

EDAP develops and markets minimally invasive medical devices, principally robotic high-intensity focused ultrasound (HIFU) systems for prostate treatment, extracorporeal shockwave lithotripsy (ESWL) equipment, and third-party distributed products. Its divisions are HIFU, ESWL, and Distribution. Strategy centers on expanding U.S. HIFU adoption and developing HIFU applications beyond prostate cancer.

Financial performance and liquidity

Metric (€ millions, except per-share data)20212020Change
Total revenue44.141.7+5.8%
Gross profit / margin18.4 / 41.8%18.4 / 44.1%Margin down 2.3 points
Operating income (loss)(1.6)0.3Lower by €1.9m
Net income (loss)0.7(1.7)Improved by €2.4m
Basic and diluted EPS€0.02(€0.06)Improved
Operating cash flow4.42.0Increased
Cash and cash equivalents at year-end47.224.7Increased €22.5m
  • Revenue mix: HIFU €9.9m (down 13.3%); ESWL €11.0m (down 14.5%); Distribution €23.1m (up 33.4%). Growth in Distribution, including Exact Imaging and lasers, more than offset declines in the other divisions.
  • HIFU device sales fell to €2.8m; the company sold seven Focal One units and no Ablatherm units, versus ten and two, respectively, in 2020. HIFU treatment-driven revenue rose 4.9% to €5.9m.
  • Cost of sales rose 10.1% to €25.6m. Management attributed the weaker gross margin primarily to a lower share of higher-margin HIFU revenue in the sales mix.
  • Operating expenses rose 10.6% to €20.0m. Selling and marketing increased 15.7% to €10.7m, and general and administrative expenses increased 36.1% to €5.9m, reflecting U.S. expansion and share-based compensation. Net R&D expense declined to €3.4m from €4.5m, partly because 2020 included €0.5m in Endo-Up discontinuation costs.
  • Net income included a €2.4m foreign-exchange gain, compared with a €1.4m loss in 2020, and €0.2m of U.S. Paycheck Protection Program loan forgiveness. The operating business remained loss-making.
  • Financing cash flow was €20.3m, principally reflecting €21.3m of net proceeds from an April 2021 ADS offering. The offering issued 4.15m shares; year-end shares outstanding were 33.47m.
  • At year-end, short-term borrowings were €1.9m and long-term debt was €5.8m. Long-term debt included €4.0m of French government-guaranteed COVID-related loans, extended to 2026, with repayments beginning in August 2022. Finance lease obligations were €0.8m; operating lease obligations were €1.6m.
  • Current assets were €67.4m and current liabilities €18.0m. Management stated working capital was sufficient for current requirements. No off-balance-sheet financing or outstanding hedging instruments were reported.

Changes, outlook, risks and unusual items

  • Outlook: Management expects R&D spending to rise to approximately 11.5% of revenue beginning in 2022 and expects selling and marketing expenses to increase as U.S. HIFU expansion accelerates. No specific revenue, operating profit, or net income guidance was provided.
  • U.S. HIFU opportunity: A Category 1 CPT code and CMS hospital and physician payment rates became effective in 2021. CMS’s 2022 average payment estimates were about $4,500 per hospital procedure and $992 for a physician in a facility setting. Private insurer coverage remains limited and subject to change.
  • Clinical and regulatory: Interim French HIFI study results presented in 2021 favored HIFU over surgery on reported recurrence-free survival and functional outcomes; final results were expected in December 2022. Focal One approval in Japan would require a clinical trial, while the company was reassessing China market access. The EU Medical Device Regulation imposes stricter compliance requirements.
  • COVID-19 and supply: The pandemic continued to delay or cancel hospital purchases and procedures, constrain travel, and disrupt access to components. Management said supply challenges had not materially affected delivery to date, but further disruption could do so.
  • Strategy and projects: The company discontinued lithotripsy R&D, including the Endo-Up platform, and stopped pursuing the original per-operative liver-cancer HECAM approach. In 2021 it repaid €0.6m of HECAM advances; €0.4m was reclassified as a non-refundable grant. HIFU work beyond prostate cancer includes endometriosis, pancreatic cancer and other potential applications.
  • Other risks: Key exposures include uncertain HIFU adoption and reimbursement, competition, lengthy sales cycles, dependence on a single French manufacturing site and some single-source suppliers, foreign-exchange movements, clinical and regulatory outcomes, and product liability. Russia represented approximately 2.5% of 2021 consolidated revenue; Russian receivables of €0.321m at year-end were paid in Q1 2022. The filing stated the company did not intend to suspend Russian operations at filing.
  • Controls and audit: KPMG issued unqualified opinions on the financial statements and internal control over financial reporting; management reported controls effective as of December 31, 2021. The audit identified revenue recognition for distinct obligations in multi-element device contracts as a critical audit matter.
  • No dividends were paid for 2016–2020, and the company did not anticipate dividends for the foreseeable future.

Important facts for investors to verify

  • Whether U.S. HIFU procedure volumes, Focal One installations, and private-payer coverage translate into recurring revenue and improved operating performance.
  • Whether the reported €0.7m net profit is sustainable without the €2.4m foreign-exchange gain and €0.2m loan forgiveness, given the €1.6m operating loss.
  • Progress on 2022 R&D and U.S. commercial spending, including execution capacity and the effect on cash use and margins.
  • Debt repayment schedule, cash availability, and any changes in hospital purchasing, COVID-related disruption, or component supply constraints.
  • Clinical study results, EU MDR compliance, and regulatory progress in Japan and China; also assess potential dilution from outstanding options and future share issuance.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.